DBV Technologies shares drop 16.5% over the week despite a rebound
The Châtillon-based biotech recovers in mid-afternoon, while the SBF 120 is slightly negative. This rebound follows several sessions of decline, as its US marketing authorization application continues and its financial position remains under close watch.
A rebound that leaves the stock below its three moving averages
The stock gains 1.71% to €1.78, among the strongest gainers of the SBF 120, while the index falls 0.15%. The move remains modest compared with the 16.59% decline recorded over the week, even though DBV Technologies still shows +13.52% over one month.
The price is below the MA20 (€1.84, a gap of 3.26%) and the MA50 (€1.88), while the MA200 at €2.79 is far away, more than 36% above the price.
The RSI at 46 signals neither overbought nor oversold conditions, and the support at €1.57 remains at a good distance. In recent days, the stock had been trading at the bottom of the index, as at the beginning of the week.
An open FDA file and a financing horizon to watch
When the 9M 2026 accounts were published on October 28, 2026, the company reported substantial doubt about its ability to continue as a going concern over twelve months, and a need for additional capital beyond the third quarter of 2027.
Among the opportunities mentioned on that occasion was the filing of the marketing authorization application for the Viaskin Peanut patch in children aged 4 to 7, with an FDA decision expected in the fourth quarter of 2026.
Furthermore, according to the declarations consulted, five funds together hold 3.59% of the capital sold short, up 0.70 points over one month. This is a high level, reflecting a non-negligible bearish positioning, although the intentions of the market participants cannot be inferred from it. The resistance level at €2.13 is the next level identified in the data.